therawis delivers industry-leading tissue and exosome proteomics contract research services from its state-of-the-art laboratory in Munich.
Tissue-based mass spectrometry exploratory and predictive biomarker studies
therawis' tissue proteomics platform accelerates biomarker discovery, target validation, and mechanism-of-action studies using both fresh frozen and FFPE tissue samples.
Starting with as little as 3 mm² of fresh frozen tissue or 3–5 µm FFPE tissue sections, we deliver deep, comprehensive proteome coverage encompassing intracellular, membrane-bound, secreted, and extracellular proteins. Our highly sensitive workflow maximizes biological insight, even from limited or precious tissue samples.
Our platform combines label-free quantitative DIA mass spectrometry with optimized sample preparation protocols and rigorous quality control to ensure exceptional data quality and reproducibility. Powered by advanced g-DIA PASEF data analysis, we achieve outstanding data completeness, highly accurate protein quantification, and scalable tissue proteomics across diverse study types.
The result is actionable biological insight—enabling researchers to uncover dysregulated pathways, identify therapeutic vulnerabilities, elucidate mechanisms of drug action, and reveal resistance mechanisms with confidence.
Exosome-based mass spectrometry exploratory and predictive biomarker studies
therawis' exosome proteomics platform enables large-scale, unbiased biomarker discovery and translational research through comprehensive proteomic profiling of exosomes isolated directly from blood plasma. Powered by our proprietary ELAEXIA® technology, the platform confidently identifies low-abundance, disease-relevant proteins, making it ideally suited for discovery studies, biomarker validation, and large cohort analyses.
We deliver deep, reproducible exosome proteome profiling with comprehensive coverage of signaling proteins, cytokines, growth factors, and other low-abundance biomarkers. Our highly quantitative workflow provides the accuracy and consistency required for large-scale clinical studies, longitudinal research, and translational applications.
At the core of the workflow is therawis' proprietary ELAEXIA® exosome isolation technology, which enables highly selective enrichment of exosomes from blood plasma and other biofluids. This superior sample preparation forms the foundation for robust downstream proteomic analysis, expanding the detectable dynamic range and significantly enhancing the identification and quantification of low-abundance proteins using label-free DIA mass spectrometry.
The result is high-confidence, biologically meaningful data that accelerates biomarker discovery, improves patient stratification, and advances the development of precision medicine.
